drugset
drugset / Trial / NCT04070209

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

NCT04070209 ↗

Phase 2 Active not recruiting 66 enrolled Sir Mortimer B. Davis - Jewish General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.

Timeline

Start
2020-10-19
Primary completion
2030-11
Completion
2030-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Darolutamide Other / unclassified 600 mg Oral

Indications

castration-resistant prostate carcinoma metastatic prostate carcinoma